Kallikrein 4 is a potential mediator of cellular interactions between cancer cells and osteoblasts in metastatic prostate cancer

Prostate

Volumn 67, Issue 4, 2007, Pages 348-360

  Gao, Jin ^a   Collard, Rachael L ^a   Bui, Loan ^a   Herington, Adrian C ^a   Nicol, David L ^b   Clements, Judith A ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

Bone metastasis; Co culture; Osteoblasts; Prostate cancer; Prostatic kallikreins

Indexed keywords

ALKALINE PHOSPHATASE; APROTININ; COMPLEMENTARY DNA; KALLIKREIN; KALLIKREIN 4; MESSENGER RNA; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER CELL; CELL INTERACTION; CELL MIGRATION; CELL PROLIFERATION; CELL TYPE; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

BONE NEOPLASMS; CELL ADHESION; CELL COMMUNICATION; CELL LINE, TUMOR; CELL MOVEMENT; COCULTURE TECHNIQUES; HUMANS; KALLIKREINS; MALE; OSTEOBLASTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RNA, MESSENGER;

EID: 33847419199     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20465     Document Type: Article

References (46)

1. Roudier MP, True LD, Higano CS, et al. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 2003;34:646-653.
2. Cher ML. Mechanisms governing bone metastasis in prostate cancer. Curr Opin Urol 2001;11:483-488.
3. Mundy GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002;2:584-593.
4. Chung LW, Baseman A, Assikis V, Zhau HE. Molecular insights into prostate cancer progression: The missing link of tumor microenvironment. J Urol 2005;173:10-20.
5. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005;5:21-28.
6. Diamandis EP, Yousef GM, Luo LY, Magklara A, Obiezu CV. The new human kallikrein gene family: Implications in carcinogenesis. Trends Endocrinol Metab 2000;11:54-60.
7. Harvey TJ, Hooper JD, Myers SA, et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000;275:37397-37406.
8. Clements JA, Willemsen NM, Myers SA, Dong Y. The tissue kallikrein family of serine proteases: Functional roles in human disease and potential as clinical biomarkers. Crit Rev Clin Lab Sci 2004;41:265-312.
9. Borgono CA, Diamandis EP. The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 2004;4:876-890.
10. Scorilas A, Plebani M, Mazza S, et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 2003;54:220-229.
11. Hooper JD, Bui LT, Rae FK, et al. Identification and characterization of KLK14, a novel kallikrein serine protease gene located on human chromosome 19q13.4 and expressed in prostate and skeletal muscle. Genomics 2001;73:117-122.
12. Killian CS, Corral DA, Kawinski E, Constantine RI. Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 1993;192:940-947.
13. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): Two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
14. Deftos LJ, Barken I, Burton DW, Hoffman RM, Geller J. Direct evidence that PTHrP expression promotes prostate cancer progression in bone. Biochem Biophys Res Commun 2005;327:468-472.
15. Shariat SF, Lamb DJ, Kattan MW, et al. Association of preoperative plasma levels of insulin-like growth factor I and insulin-like growth factor binding proteins-2 and -3 with prostate cancer invasion, progression, and metastasis. J Clin Oncol 2002;20:833-841.
16. Stephenson SA, Verity K, Ashworth LK, Clements JA. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem 1999;274:23210-23214.
17. Nelson PS, Gan L, Ferguson C, et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci USA 1999;96:3114-3119.
18. Simmer JP, Fukae M, Tanabe T, et al. Purification, characterization, and cloning of enamel matrix serine proteinase 1. J Dent Res 1998;77:377-386.
19. Hu JC, Zhang C, Sun X, et al. Characterization of the mouse and human PRSS17 genes, their relationship to other serine proteases, and the expression of PRSS17 in developing mouse incisors. Gene 2000;251:1-8.
20. Yousef GM, Obiezu CV, Luo LY, Black MH, Diamandis EP. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res 1999;59:4252-4256.
21. Hu JC, Sun X, Zhang C, et al. Enamelysin and kallikrein-4 mRNA expression in developing mouse molars. Eur J Oral Sci 2002;110:307-315.
22. Obiezu CV, Soosaipillai A, Jung K, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 2002;48:1232-1240.
23. Takayama TK, McMullen BA, Nelson PS, Matsumura M, Fujikawa K. Characterization of hK4 (prostase), a prostate-specific serine protease: Activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 2001;40:15341-15348.
24. Matsumura M, Bhatt AS, Andress D, et al. Substrates of the prostate-specific serine protease prostase/KLK4 defined by positional-scanning peptide libraries. Prostate 2005;62:1-13.
25. Harvey TJ, Dong Y, Bui L, et al. Production and characterization of antipeptide kallikrein 4 antibodies. Use of computer modeling to design peptides specific to Kallikrein 4. Methods Mol Med 2003;81:241-254.
26. Veveris-Lowe TL, Lawrence MG, Collard RL, Bui LT, Herington AC, Nicol D, Clements JA. Kallikrein 4 (hK4) and Prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr Relat Cancer 2005;12:617-629.
27. Nemeth JA, Harb JF, Barroso U, Jr., et al. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999;59:1987-1993.
28. Lang SH, Hyde C, Reid IN, et al. Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. Prostate 2002;52:253-263.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;6555-63.
30. Gao J, Symons AL, Haase H, Bartold PM. Should cementoblasts express alkaline phosphatase activity? Preliminary study of rat cementoblasts in vitro. J Periodontol 1999;70:951-959.
31. Whelan JA, Russell NB, Whelan MA. A method for the absolute quantification of cDNA using real-time PCR. J Immunol Methods 2003;278:261-269.
32. Saito K, Oku T, Ata N, et al. A modified and convenient method for assessing tumor cell invasion and migration and its application to screening for inhibitors. Biol Pharm Bull 1997;20:345-348.
33. Romanov VI, Goligorsky MS. RGD-recognizing integrins mediate interactions of human prostate carcinoma cells with endothelial cells in vitro. Prostate 1999;39:108-118.
34. Saedi MS, Zhu Z, Marker K, et al. Human kallikrein 2 (hK2), but not prostate-specific antigen (PSA), rapidly complexes with protease inhibitor 6 (PI-6) released from prostate carcinoma cells. Int J Cancer 2001;94:558-563.
35. Yang J, Fizazi K, Peleg S, et al. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway. Cancer Res 2001;61:5652-5659.
36. Corey E, Quinn JE, Bladou F, et al. Establishment and characterization of osseous prostate cancer models: Intra-tibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
37. Fizazi K, Sikes CR, Kim J, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in pre-clinical models of advanced prostate cancer. Anticancer Res 2004;24:2897-2903.
38. Juretic N, Santibanez JF, Hurtado C, Martinez J. ERK 1,2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. J Cell Biochem 2001;83:92-98.
39. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 1999;59:4453-4457.
40. Pinski J, Parikh A, Bova GS, Isaacs JT. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. Cancer Res 2001;61:6372-6376.
41. Martinez J, Silva S, Santibanez JF. Prostate-derived soluble factors block osteoblast differentiation in culture. J Cell Biochem 1996;61:18-25.
42. Korkmaz KS, Korkmaz CG, Pretlow TG, Saatcioglu F. Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: Intracellular localization, alternative cDNA forms, and regulation by multiple hormones. DNA Cell Biol 2001;20:435-445.
43. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 2004;64:2365-2370.
44. Simmer JP, Bartlett JD. Kallikrein 4 is a secreted protein. Cancer Res 2004;64:8481-8482; author reply 8482-8483.
45. Bonfil RD, Osenkowski P, Fridman R, Cher ML. Matrix metalloproteinaes and bone metastasis. Cancer Treat Res 2004;118:173-195.
46. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48:1-6.